Wilmington, DE, United States of America

Nora Eibergen

This inventor holds 1 USPTO granted patent and 2 published patent applications. Top assignee: Mc (US) 3 LLC. Active years: 2023.

USPTO Granted Patents = 1 

% Patents Active = 100.0

Average Co-Inventor Count = 2.0

ph-index = 1


Company Filing History:


Years Active: 2023

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Nora Eibergen: Innovator in Antimicrobial Compositions

Introduction

Nora Eibergen is a notable inventor based in Wilmington, Delaware. She has made significant contributions to the field of antimicrobial compositions. Her innovative work has led to the development of a unique patent that showcases her expertise and creativity.

Latest Patents

Nora Eibergen holds a patent for a synergistic combination of 1,3-bis(hydroxymethyl)-5,5-dimethylimidazolidine-2,4-dione with glyoxal. This patent describes a synergistic antimicrobial composition that consists of two key components. The first component is 1,3-bis(hydroxymethyl)-5,5-dimethylimidazolidine-2,4-dione, while the second component is glyoxal, which acts as a hydrogen sulfide scavenger. This innovative combination enhances the antimicrobial properties of the composition.

Career Highlights

Nora Eibergen is currently associated with Mc (US) 3 LLC, where she continues to advance her research and development efforts. Her work at the company reflects her commitment to innovation and excellence in the field of antimicrobial solutions.

Collaborations

Nora collaborates with Geert Van Der Kraan, contributing to the advancement of their shared goals in research and development. Their partnership exemplifies the importance of teamwork in driving innovation.

Conclusion

Nora Eibergen is a pioneering inventor whose work in antimicrobial compositions has made a significant impact. Her patent and ongoing contributions to the field highlight her dedication to innovation and excellence.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…